The Annual General Meeting of Bioventix Plc (the “Company”) will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on Thursday 6 December 2018 commencing at 2.00pm.
Director’s report and financial statements for the year ended 30th June 2018.
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2018. Click here for pdf version.
Highlights:
Bioventix plc
(“Bioventix” or “the Company”)
Notice of Results and Notice of AGM
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it will release its preliminary results for the year ended 30 June 2018 on 8 October 2018.
The Company’s Annual General Meeting will be held on Thursday 6 December at 2.00p.m at Farnham Castle, Castle Street, Farnham, Surrey, GU9 0AG.
TR-1: Notification of major interest in shares.
TR-1: Notification of major interest in shares. (more…)
Unaudited interim results for the six months ended 31st December 2017. (more…)
Unaudited interim results for the six months ended 31st December 2017. (more…)
TR-1: Notification of major interest in shares. (more…)
Bioventix plc
(“Bioventix” or the “Company”)
Result of AGM
Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed.